Showing 1191-1200 of 1319 results for "".
- Lecanemab, an Antibody to Amyloid Beta, Reduced Amyloid Levels and Cognitive Declinehttps://practicalneurology.com/news/lecanemab-an-antibody-to-amyloid-beta-reduced-amyloid-levels-and-cognitive-decline/2469653/Preliminary assessment of results clinical trials of lecanemab (BAN2401; Biogen, Cambridge, MA; Eisai, Tokyo, Japan) for potential treatment of Alzheimer disease (AD), were presented at the Alzheimer’s Association International Conference July 26-30, 2021. Lecanemab reduced brain
- Cases of Dementia Projected to Increase Worldwidehttps://practicalneurology.com/news/cases-of-dementia-projected-to-increase-worldwide/2469646/Data presented at the Alzheimer's Association International Congress July 26-30, 2021 show that all types of dementia have been on the rise in recent years and are predicted to increase further. Rates of early-onset dementia are also increasing, and in the US, mortality from Alzheimer diseae
- Healthy Midlife Choices May Reduce Risk of Stroke in Womenhttps://practicalneurology.com/news/healthy-midlife-choices-may-reduce-risk-of-stroke-in-women/2469224/A study published in Stroke shows better eating habits, maintaining a healthy weight, exercising, and not smoking beginning at midlife may still significantly reduce stroke risk. During the 26-year follow-up, researchers found: • smoking cessation, da
- Metabolic Regulator Shows Promise for Life-Saving Treatment of Thymidine Kinase Deficiency Disordershttps://practicalneurology.com/news/metabolic-regulator-shows-promise-for-life-saving-treatment-of-thymidine-kinase-deficiency-disorders/2469047/In a global phase 2 study of pyrimidine nucleoside substrate enhancement therapy (SET) (MT1621; Modis Therapeutics/Zogenix, Oakland, CA) for treating thymidine kinase 2 (TK2) deficiency all treated participants survived. Most individuals treated with SET had improved (68%) or stabilized (26%) mot
- Non-Opioid Drug Significantly Reduced Pain After Surgery, Studies Revealhttps://practicalneurology.com/news/non-opioid-drug-significantly-reduced-pain-after-surgery-studies-reveal/2474650/Treatment with MR-107A-02 (meloxicam; Viatris, Pittsburgh, PA), a novel, oral, fast-acting formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, was shown to significantly reduce pain and opioid usage vs placebo in top-line results from 2 phase 3 clinical studies. Additionally
- Gene Therapy Shown to Improve Motor Ability for Children with SMAhttps://practicalneurology.com/news/gene-therapy-shown-to-improve-motor-ability-for-children-with-sma/2473812/Treatment with OAV101 IT (intrathecal onasemnogene abeparvovec; Novartis, Cambridge, MA) was associated with significant improvements in motor ability when administered to children with spinal muscular atrophy type 2 (SMA 2). Top-line results of the phase 3 STEER clinical study (NCT05089656) pres
- Large Scale Survey of Patients with MS Uncovers Significant Barriers to Care: 42% of Respondents Do Not See an MS Specialisthttps://practicalneurology.com/news/large-scale-survey-of-ms-patient-needs-uncovers-significant-barriers-to-care-42-do-not-see-an-ms-specialist/2470481/Results from a large-scale, national survey highlight the significant barriers that people living with multiple sclerosis (MS) face in accessing resources and health care in the United States. The top barriers identified from the survey commissioned by The Multiple Sclerosis Association of Americ
- First Participant Dosed with Buntanetap in Phase 3 Trial for Early Parkinson Diseasehttps://practicalneurology.com/news/first-participant-dosed-with-buntanetap-in-phase-3-trial-for-early-parkinson-disease/2470008/In a phase 3 clinical trial for early Parkinson disease (PD) treatment, the first participant was dosed with buntanetap (ANVS401; Annovis, Berwyn, PA). Planned enrollment is 450 participants with early PD who will be randomly assigned to receive 10 or 20 mg buntanetap or placebo, on top of t
- Shine Forward with Dravet, Support Resource for Parents of Children Living with Dravet Syndrome Launchedhttps://practicalneurology.com/news/shine-forward-with-dravet-support-resource-for-parents-of-children-living-with-dravet-syndrome-launched/2469264/A new resource for parents of children with Dravet syndrome (DS), Shine Forward with Dravethas been launched by pharmaceutical company Zogenix (Emeryville, CA). The website includes a unique set of online tips, tools, and advice from families and is designed to inspire deeper connections between
- Mediterranean Diet Associated with Lower Risk of Stroke in Womenhttps://practicalneurology.com/news/mediterranean-diet-associated-with-lower-risk-of-stroke-in-women/2485701/Greater adherence to a Mediterranean-style dietary pattern was associated with a lower risk of stroke among women, according to a study published in Neurology Open Access. Although the association was observed for both ischemic and hemorrhagic strokes, the strongest reductions in risk we